Insight Molecular Diagnostics, Inc. (IMDX)
4.14
+0.13
(+3.24%)
USD |
NASDAQ |
Sep 22, 16:00
4.115
-0.02
(-0.60%)
After-Hours: 20:00
Insight Molecular Diagnostics Gross Profit Margin (Quarterly) : -202.5% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -202.5% |
| March 31, 2026 | -1.89K% |
| December 31, 2025 | -4.13% |
| September 30, 2025 | -162.7% |
| June 30, 2025 | -38.80% |
| March 31, 2025 | 40.27% |
| December 31, 2024 | 2.86% |
| September 30, 2024 | -233.0% |
| June 30, 2024 | -221.6% |
| March 31, 2024 | -190.3% |
| December 31, 2023 | -37.26% |
| September 30, 2023 | -17.02% |
| June 30, 2023 | -17.28% |
| Date | Value |
|---|---|
| March 31, 2023 | -118.9% |
| September 30, 2022 | -2.41K% |
| June 30, 2022 | -551.1% |
| March 31, 2022 | -254.7% |
| December 31, 2021 | 38.14% |
| September 30, 2021 | -88.01% |
| June 30, 2021 | -19.41% |
| March 31, 2021 | 7.03% |
| December 31, 2020 | -42.35% |
| September 30, 2020 | -8.29% |
| June 30, 2020 | -155.2% |
| March 31, 2020 | -981.2% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Perspective Therapeutics, Inc. | -1.31K% |
| Agenus, Inc. | 98.50% |
| Amgen, Inc. | 72.08% |
| Anika Therapeutics, Inc. | 65.15% |
| BioCryst Pharmaceuticals, Inc. | 98.01% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -129.8% |
| Profit Margin (Quarterly) | -4.71K% |
| Operating Margin (Quarterly) | -3.80K% |
| Return on Net Operating Assets | -337.7% |